ІНГІБІТОРИ ЦИКЛООКСИГЕНАЗИ-2 В ТЕРАПІЇ КІШОК ІЗ ПУХЛИНАМИ МОЛОЧНОЇ ЗАЛОЗИ (КОРОТКИЙ ОГЛЯД)
DOI:
https://doi.org/10.37000/abbsl.2023.108.17Ключові слова:
кішки, новоутворення молочної залози, циклооксигеназа-2, нестероїдні протизапальні засобиАнотація
Прогресивне збільшення частки кішок із новоутвореннями молочної залози на тлі недостатньої ефективності лікування обумовлює необхідність розробки і впровадження альтернативних схем лікування. Одним із перспективних напрямків є вплив на прозапальну ланку, зокрема шляхом гальмування синтезу циклооксигенази-2. За неоплазій молочної залози у кішок доведена протипухлинна активність мелоксикаму, робенакоксибу, аспірину, піроксикаму. У 30 % пацієнтів побічні ефекти при їх використанні короткочасні і не потребують корекції, тільки у 10 % випадків зумовлюють необхідність переривання терапії. Наразі перспективним напрямком є дослідження можливості довготривалого застосування в онкохворих кішок інгібіторів циклооксигенази-2.
Посилання
Anderson, D. (2014). Mammary tumours in the dog and cat (part 2): surgical management. Companion Animal, 19(12), 648–653. https://doi.org/10.12968/coan.2014.19.12.648
Asghar, W., & Jamali, F. (2015). The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology, 23, 1–16. https://doi.org/10.1007/s10787-014-0225-9
Beam, S. L., Rassnick, K. M., Moore, A. S., & McDonough, S. P. (2003). An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms. Veterinary Pathology, 40(5), 496–500. https://doi.org/10.1354/vp.40-5-496
Benavente, M. A., Bianchi, C. P., & Aba, M. A. (2016). Canine Mammary Tumors: Risk Factors, Prognosis and Treatments. J. Vet. Adv, 6(8), 1291–1300. https://doi.org/ 10.5455/jva.20160916045115
Borrego, J. F., Cartagena, J. C., & Engel, J. (2009). Treatment of feline mammary tumours using chemotherapy, surgery and a COX‐2 inhibitor drug (meloxicam): A retrospective study of 23 cases (2002–2007). Veterinary and comparative oncology, 7(4), 213–221. https://doi.org/10.1111/j.1476-5829.2009.00194.x
Brandi, A., de Faria Lainetti, P., Elias, F., Rodrigues, M. M. P., Fagundes Moraes, L., Laufer-Amorim, R., ... & Fonseca-Alves, C. E. (2022). Firocoxib as a Potential Neoadjuvant Treatment in Canine Patients with Triple-Negative Mammary Gland Tumors. Animals, 13(1), 60. https://doi.org/10.3390/ani13010060
Bulman-Fleming, J. C., Turner, T. R., & Rosenberg, M. P. (2010). Evaluation of adverse events in cats receiving long-term piroxicam therapy for various neoplasms. Journal of feline medicine and surgery, 12(4), 262–268. https://doi.org/10.1016/j.jfms.2009.09.007
Charlton, A. N., Benito, J., Simpson, W., Freire, M., & Lascelles, B. D. X. (2013). Evaluation of the clinical use of tepoxalin and meloxicam in cats. Journal of feline medicine and surgery, 15(8), 678–690. https://doi.org/10.1177/1098612X12473994
Coruzzi, G., Menozzi, A., & Dobrilla, G. (2004). Novel non-steroidal anti-inflammatory drugs: what we have learned from animal studies. Current Drug Targets-Inflammation & Allergy, 3(1), 43–61. https://doi.org/10.2174/1568010043483971
Doré, M. (2011). Cyclooxygenase-2 expression in animal cancers. Veterinary pathology, 48(1), 254–265. https://doi.org/10.1177/0300985810379434
Giraudel, J. M., Toutain, P. L., & Lees, P. (2005). Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and predicting selectivity of nonsteroidal anti-inflammatory drugs in cats. American Journal of Veterinary Research, 66(4), 700–709. https://doi.org/10.2460/ajvr.2005.66.700
Goodman, L. A., Torres, B. T., Reynolds, L. R., & Budsberg, S. C. (2010). Effects of firocoxib, meloxicam, and tepoxalin administration on eicosanoid production in target tissues of healthy cats. American journal of veterinary research, 71(9), 1067–1073. https://doi.org/10.2460/ajvr.71.9.1067
Hassan, M. H., El-Beshbishy, H. A., Aly, H., Attia, S. M., Bahashwan, S. A., & Ghobara, M. M. (2014). Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice. Cancer chemotherapy and pharmacology, 74, 559–569. https://doi.org/10.1007/s00280-014-2544-3
Hayes, A. (2007). Cancer, cyclo‐oxygenase and nonsteroidal anti‐inflammatory drugs–can we combine all three?. Veterinary and comparative oncology, 5(1), 1–13. https://doi.org/10.1111/j.1476-5829.2006.00111.x
Heeb, H. L., Chun, R., Koch, D. E., Moore, L., Radlinsky, M., Corse, M., ... & Hunter, R. P. (2005). Multiple dose pharmacokinetics and acute safety of piroxicam and cimetidine in the cat. Journal of veterinary pharmacology and therapeutics, 28(5), 447–452. https://doi.org/10.1111/j.1365-2885.2005.00682.x
Heeb, H. L., Chun, R., Koch, D. E., Goatley, M. A., & Hunter, R. P. (2003). Single dose pharmacokinetics of piroxicam in cats. Journal of veterinary pharmacology and therapeutics, 26(4), 259–263. https://doi.org/10.1046/j.1365-2885.2003.00479.x
Heit, M. C., Stallons, L. J., Seewald, W., Thompson, C. M., Toutain, C. E., King, S. B., & Helbig, R. (2020). Safety evaluation of the interchangeable use of robenacoxib in commercially-available tablets and solution for injection in cats. BMC veterinary research, 16(1), 355. https://doi.org/10.1186/s12917-020-02553-7
Kamata, M., King, J. N., Seewald, W., Sakakibara, N., Yamashita, K., & Nishimura, R. (2012). Comparison of injectable robenacoxib versus meloxicam for peri-operative use in cats: results of a randomised clinical trial. Veterinary journal (London, England: 1997), 193(1), 114–118. https://doi.org/10.1016/j.tvjl.2011.11.026
Keepman, S. J., & Pellin, M. A. (2022). Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats. Journal of Feline Medicine and Surgery, 24(12), 1187–1194. https://doi.org/10.1177/1098612X211067023
King, J. N., Dawson, J., Esser, R. E., Fujimoto, R., Kimble, E. F., Maniara, W., ... & Lees, P. (2009). Preclinical pharmacology of robenacoxib: A novel selective inhibitor of cyclooxygenase‐2. Journal of veterinary pharmacology and therapeutics, 32(1), 1–17. https://doi.org/10.1111/j.1365-2885.2008.00962.x
King, J. N., Hotz, R., Reagan, E. L., Roth, D. R., Seewald, W., & Lees, P. (2012). Safety of oral robenacoxib in the cat. Journal of veterinary pharmacology and therapeutics, 35(3), 290–300. https://doi.org/10.1111/j.1365-2885.2011.01320.x
King, J. N., Panteri, A., Graille, M., Seewald, W., Friton, G., & Desevaux, C. (2016). Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in cats. BMC Veterinary Research, 12, 1–15. https://doi.org/10.1186/s12917-016-0734-4
Lascelles, B. D. X., Court, M. H., Hardie, E. M., & Robertson, S. A. (2007). Nonsteroidal anti-inflammatory drugs in cats: a review. Veterinary anaesthesia and analgesia, 34(4), 228–250. https://doi.org/10.1111/j.1467-2995.2006.00322.x
Lees, P., Toutain, P. L., Elliott, J., Giraudel, J. M., Pelligand, L., & King, J. N. (2022). Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. Journal of veterinary pharmacology and therapeutics, 45(4), 325–351. https://doi.org/10.1111/jvp.13052
Li, J., Chen, X., Dong, X., Xu, Z., Jiang, H., & Sun, X. (2006). Specific COX‐2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells. Journal of gastroenterology and hepatology, 21(12), 1814–1820. https://doi.org/10.1111/j.1440-1746.2006.04366.x
Millanta, F., Asproni, P., Canale, A., Citi, S., & Poli, A. (2016). COX‐2, mPGES‐1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours. Veterinary and Comparative Oncology, 14(3), 270–280. https://doi.org/10.1111/vco.12096
Millanta, F., Citi, S., Della Santa, D., Porciani, M., & Poli, A. (2006). COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic fmolecular markers. Breast cancer research and treatment, 98, 115–120. https://doi.org/10.1007/s10549-005-9138-z
Morrison, W. B. (2012). Inflammation and cancer: a comparative view. Journal of veterinary internal medicine, 26(1), 18–31. https://doi.org/10.1111/j.1939-1676.2011.00836.x
Morré, D. J., & Morre, D. M. (2006). tNOX, an alternative target to COX-2 to explain the anticancer activities of non-steroidal anti-inflammatory drugs (NSAIDS). Molecular and cellular biochemistry, 283, 159–167. https://doi.org/10.1007/s11010-006-2568-z
Petrucci, G. N., Henriques, J., Lobo, L., Vilhena, H., Figueira, A. C., Canadas‐Sousa, A., ... & Queiroga, F. L. (2021). Adjuvant doxorubicin vs metronomic cyclophosphamide and meloxicam vs surgery alone for cats with mammary carcinomas: A retrospective study of 137 cases. Veterinary and comparative oncology, 19(4), 714–723. https://doi.org/10.1111/vco.12660
Sayasith, K., Sirois, J., & Doré, M. (2009). Molecular characterization of feline COX-2 and expression in feline mammary carcinomas. Veterinary Pathology, 46(3), 423–429. https://doi.org/10.1354/vp.08-VP-0161-D-FL
Sparkes, A. H., Heiene, R., Lascelles, B. D. X., Malik, R., Real, L., Robertson, S., ... & Taylor, P. (2010). ISFM and AAFP consensus guidelines: long-term use of NSAIDs in cats. Journal of feline medicine and surgery, 12(7), 521–538. https://doi.org/10.1016/j.jfms.2010.05.004
Thun, M. J., Henley, S. J., & Patrono, C. (2002). Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. Journal of the National Cancer Institute, 94(4), 252–266. https://doi.org/10.1093/jnci/94.4.252
Xu, E., Hu, M., & Liu, Y. (2021). Aspirin inhibits proliferation and metastasis of canine mammary gland tumor cells through Wnt signaling axis. Translational cancer research, 10(2), 589–601. https://doi.org/10.21037/tcr-20-3172
Yang, C., Liu, J., Wang, Y., Tong, J., Wu, Y., & Liu, Y. (2017). Aspirin inhibits the proliferation of canine mammary gland tumor cells in vitro and in vivo. Translational Cancer Research, 6(1). https://doi.org/10.21037/tcr.2017.01.07
Yoshitake, R., Saeki, K., Watanabe, M., Nakaoka, N., Ong, S. M., Hanafusa, M., ... & Nakagawa, T. (2017). Molecular investigation of the direct anti-tumour effects of nonsteroidal anti-inflammatory drugs in a panel of canine cancer cell lines. The Veterinary Journal, 221, 38–47. https://doi.org/10.1016/j.tvjl.2017.02.001
